| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.24 | 1e-06 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.39 | 3e-05 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.38 | 6e-05 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.37 | 7e-05 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.34 | 0.0001 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | 0.61 | 0.0008 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.22 | 0.0008 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.32 | 0.001 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.54 | 0.002 |